Medical Center Teodora EOOD
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Medical Center Teodora EOOD researchers are exploring innovative approaches to lower cardiovascular risk in patients with established disease or high‑risk profiles. Current studies focus on reducing major adverse cardiac events, preventing heart‑failure progression, and improving blood‑pressure control through novel lipid‑lowering agents and combination therapies.
- Inclisiran for LDL‑C reduction in atherosclerotic disease
- Zilebesiran targeting hypertension and cardiovascular outcomes
- Baxdrostat combined with dapagliflozin to prevent heart failure
- Evaluation of long‑term safety of RNA‑based therapies
- Assessment of cardiovascular event reduction in high‑risk cohorts
With 18 investigators leading 16 trials, the site contributes valuable data to European cardiovascular research networks.
Immune System Diseases
The center’s immune‑focused program investigates targeted biologics for conditions such as Sjögren's disease and related autoimmune disorders. Trials aim to determine whether new antibodies can modulate disease activity and improve patient‑reported outcomes.
- Nipocalimab efficacy in moderate to severe Sjögren's disease
- Biomarker analysis for immune response modulation
- Safety profiling of novel monoclonal antibodies
- Comparative studies with placebo in autoimmune populations
- Exploration of patient‑centered quality‑of‑life measures
These investigations support the broader effort to expand therapeutic options for patients with systemic immune dysfunction.
Musculoskeletal Diseases
In the musculoskeletal arena, Medical Center Teodora EOOD is conducting multiple studies on inflammatory arthritis, including rheumatoid arthritis and psoriatic arthritis. The trials evaluate new biologics, biosimilars, and oral agents to achieve better joint control and reduce disease progression.
- Bimekizumab versus risankizumab in active psoriatic arthritis
- Sonelokimab dosing strategies and long‑term safety
- MB04 biosimilar comparison with Enbrel® in rheumatoid arthritis
- AP1189 combined with methotrexate for early rheumatoid arthritis
- IMVT‑1402 assessment in ACPA‑positive rheumatoid arthritis
Across 16 studies, the site engages rheumatology experts to advance treatment paradigms for debilitating joint diseases.
Nervous System Diseases
A focused neurological trial at the center evaluates a novel compound for patients experiencing focal onset seizures. The objective is to assess seizure frequency reduction and overall safety compared with standard care.
- SPN‑817 efficacy in adult focal seizures
- Dose‑response analysis of the investigational agent
- Monitoring of adverse events and tolerability
- Impact on quality of life for seizure patients
- Integration of electroencephalogram biomarkers
The study adds to the limited pool of European data on emerging antiepileptic therapies.
Skin and Connective Tissue Diseases
Research on skin‑related connective disorders centers on improving outcomes for patients with psoriatic arthritis and related skin manifestations. Trials test next‑generation biologics to alleviate joint pain while also addressing skin lesions.
- Guselkumab efficacy in active psoriatic arthritis
- Comparative assessment of sonelokimab versus placebo and risankizumab
- Long‑term safety monitoring of biologic treatments
- Evaluation of patient‑reported skin symptom improvement
- Exploration of treatment‑naïve versus biologic‑experienced cohorts
The site’s multidisciplinary team bridges dermatology and rheumatology to deliver comprehensive care options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 95 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 94 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 15 by active trials.
- 1AstraZeneca AB3active
lock +14 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center Teodora EOOD
lock Showing 1 of 61 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 95 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues | 5 | Unknown | 2024-10-31 | 2025-12-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.